

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma [ID2712]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb (nivolumab, ipilimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Cancer Black Care • Cancer Equality • Cancer 52 • Guts UK • GIST Cancer UK • Heartburn Cancer UK • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Ochre • Oesophageal Patients Association • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland • British Association of Surgical Oncology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK • Primary Care Society for Gastroenterology • Royal College of Anaesthetists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (capecitabine, cisplatin, epirubicin, fluorouracil, oxaliplatin) • Dr Reddy's Laboratories (capecitabine) • Fresenius Kabi (oxaliplatin) • Glenmark Pharmaceuticals Europe (capecitabine) • Hospira UK (cisplatin, fluorouracil, oxaliplatin) • Medac GmbH (epirubicin, fluorouracil, oxaliplatin) • Merck Sharp & Dohme (UK) (pembrolizumab) • Morningside Healthcare (capecitabine) • Mylan (epirubicin) • Pfizer (cisplatin, epirubicin, fluorouracil, oxaliplatin)

Final stakeholder list for the technology appraisal of nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma.

Issue date: January 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Hillingdon CCG • NHS Rushcliffe CCG • Welsh Government 	<ul style="list-style-type: none"> • Sandoz (cisplatin) • Seacross Pharmaceuticals (oxaliplatin) • Sun Pharmaceutical Industries Europe (oxaliplatin) • Teva (cisplatin, epirubicin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Upper Gastrointestinal and Pancreatic Diseases Group • Cochrane UK • Genomics England • Guts UK • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Oracle Cancer Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.